[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Indexing Sources::
Editorial Board::
Executive Members::
Articles Archive::
Instruction to Authors::
Contact Us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 25, Issue 2 (7-2023) ::
J Gorgan Univ Med Sci 2023, 25(2): 12-21 Back to browse issues page
Laser Therapy in Corneal Refractive of Patients with Systemic Autoimmune Disorders
Mohammad-Reza Ansari-Astaneh1 , Acieh Es’haghi2 , Elahe Keshavarzian3 , Javad Sadeghi1 , Mohammad Yaser Kiarudi * 4
1- Assistant Professor of Ophthalmology, Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2- Assistant Professor of Cornea & External Eye Diseases, Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
3- M.Sc in Nursing, Department of Medical - Surgical, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
4- Assistant Professor of Ophthalmology, Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. , y_kia76@yahoo.com
Abstract:   (1257 Views)

The rise in patients seeking corneal refractive surgery, despite having systemic autoimmune diseases, underscores the need for special considerations when treating these individuals. Recent studies have expanded our knowledge in identifying and evaluating autoimmune disorders and their potential side effects in the results of corneal refractive surgery with laser. This study briefly examines the pathogenic factors, clinical aspects, and possible complications in patients with systemic autoimmune disorders subjected to these surgeries. In total, 132 articles were selected for this research among the reviewed studies. Considering that the release of various cytokines caused by systemic autoimmune disorders can lead to destructive corneal consequences, the need for early diagnosis before any laser surgery for refractive errors seems essential. Although procedures such as LASIK and PRK are commonly performed on patients with autoimmune disorders, important considerations must be made. Studies have not yet confirmed definitive contraindications to laser refractive surgery for autoimmune disorders.

Keywords: Autoimmune Disease [MeSH], Cornea [MeSH], Refractive Surgery [MeSH], Photorefractive Keratectomy [MeSH], Laser in-situ Keratomileusis [MeSH]
Article ID: Vol25-16
Full-Text [PDF 773 kb]   (2069 Downloads)    
Type of Study: Review Article | Subject: Ophtalmology
1. Etezad-Razavi M, Tafaghodi-Yousefi B, Eslampour A, Kiarudi MY, Najjaran M, Momeni-Moghaddam H, et al. Visual outcomes of photorefractive keratectomy in non-children with anisometropic amblyopia: One-year Follow-up Outcomes. Eur J Ophthalmol. 2022 Sep; 32(5): 2615-21. doi: 10.1177/11206721211073033. [DOI] [PubMed]
2. Fallah Tafti M, Heidarian Sh, Kiarudi MY, Mohammadpour M, Majdi Nasab M. The role of corneal volume distribution and percentage increase in volume in detection of mild and moderate keratoconus. Iranian Journal of Ophthalmology. 2010; 22(4): 49-58. [Link]
3. Mohamadpour M, Khorrami-Nejad M, Kiarudi MY, Khosravi K. Evaluating the Ectasia Risk Score System in Cancelled Laser In Situ Keratomileusis Candidates. J Ophthalmic Vis Res. 2020 Oct; 15(4): 481-85. doi: 10.18502/jovr.v15i4.7788. [DOI] [PubMed]
4. Liang L, Zhang M, Zou W, Liu Z. Aggravated dry eye after laser in situ keratomileusis in patients with Sjögren syndrome. Cornea. 2008 Jan; 27(1): 120-23. doi: 10.1097/ICO.0b013e318158312f. [DOI] [PubMed]
5. Toda I, Asano-Kato N, Hori-Komai Y, Tsubota K. Laser-assisted in situ keratomileusis for patients with dry eye. Arch Ophthalmol. 2002 Aug; 120(8): 1024-28. doi: 10.1001/archopht.120.8.1024. [DOI] [PubMed]
6. Aman-Ullah M, Gimbel HV, Purba MK, van Westenbrugge JA. Necrotizing keratitis after laser refractive surgery in patients with inactive inflammatory bowel disease. Case Rep Ophthalmol. 2012 Jan; 3(1): 54-60. doi: 10.1159/000336567. [DOI] [PubMed]
7. Carp GI, Verhamme T, Gobbe M, Ayliffe WH, Reinstein DZ. Surgically induced corneal necrotizing keratitis following LASIK in a patient with inflammatory bowel disease. J Cataract Refract Surg. 2010 Oct; 36(10): 1786-89. doi: 10.1016/j.jcrs.2010.06.046. [DOI] [PubMed]
8. Cobo-Soriano R, Beltrán J, Baviera J. LASIK outcomes in patients with underlying systemic contraindications: a preliminary study. Ophthalmology. 2006 Jul; 113(7): 1118.e1-8. doi: 10.1016/j.ophtha.2006.02.023. [DOI] [PubMed]
9. Liu MP, Hwang FS, Dunn JP, Stark WJ, Bower KS. Hypopyon uveitis following LASIK in a patient with ulcerative colitis. J Refract Surg. 2012 Aug; 28(8): 589-91. doi: 10.3928/1081597X-20120722-02. [DOI] [PubMed]
10. Smith RJ, Maloney RK. Laser in situ keratomileusis in patients with autoimmune diseases. J Cataract Refract Surg. 2006 Aug; 32(8):1292-95. doi: 10.1016/j.jcrs.2006.02.059. [DOI] [PubMed]
11. Alió JL, Artola A, Belda JI, Perez-Santonja JJ, Muñoz G, Javaloy J, Rodríguez-Prats JL, et al. LASIK in patients with rheumatic diseases: a pilot study. Ophthalmology. 2005 Nov; 112(11): 1948-54. doi: 10.1016/j.ophtha.2005.06.022. [DOI] [PubMed]
12. Lahners WJ, Hardten DR, Lindstrom RL. Peripheral keratitis following laser in situ keratomileusis. J Refract Surg. 2003 Nov-Dec; 19(6): 671-75. doi: 10.3928/1081-597X-20031101-10. [DOI] [PubMed]
13. Cua IY, Pepose JS. Late corneal scarring after photorefractive keratectomy concurrent with development of systemic lupus erythematosus. J Refract Surg. 2002 Nov-Dec; 18(6): 750-52. doi: 10.3928/1081-597X-20021101-16. [DOI] [PubMed]
14. Díaz-Valle D, Benítez del Castillo JM, Castillo A, Sayagués O, Bañares A, García-Sánchez J. Immunologic and clinical evaluation of postsurgical necrotizing sclerocorneal ulceration. Cornea. 1998 Jul; 17(4): 371-75. doi: 10.1097/00003226-199807000-00005. [DOI] [PubMed]
15. Gottsch JD, Akpek EK. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc. 2000; 98: 81-87. [PubMed]
16. Zhao J, Nagasaki T. Mechanical damage to corneal stromal cells by epithelial scraping. Cornea. 2004 Jul; 23(5): 497-502. doi: 10.1097/01.ico.0000114129.63670.ab. [DOI] [PubMed]
17. Yang HY, Fujishima H, Toda I, Itoh S, Bissen-Miyajima H, Shimazaki J, et al. Allergic conjunctivitis as a risk factor for regression and haze after photorefractive keratectomy. Am J Ophthalmol. 1998 Jan; 125(1):54-58. doi: 10.1016/s0002-9394(99)80234-7. [DOI] [PubMed]
18. Meyer JC, Stulting RD, Thompson KP, Durrie DS. Late onset of corneal scar after excimer laser photorefractive keratectomy. Am J Ophthalmol. 1996 May; 121(5): 529-39. doi: 10.1016/s0002-9394(14)75427-3. [DOI] [PubMed]
19. Campos M, Takahashi R, Tanaka H, Chamon W, Allemann N. Inflammation-related scarring after photorefractive keratectomy. Cornea. 1998 Nov; 17(6): 607-10. doi: 10.1097/00003226-199811000-00007. [DOI] [PubMed]
20. Simpson RG, Moshirfar M, Edmonds JN, Christiansen SM, Behunin N. Laser in situ keratomileusis in patients with collagen vascular disease: a review of the literature. Clin Ophthalmol. 2012; 6: 1827-37. doi: 10.2147/OPTH.S36690. [DOI] [PubMed]
21. Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007 Dec; 46(12): 1757-62. doi: 10.1093/rheumatology/kem173. [DOI] [PubMed]
22. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009 Feb; 147(2): 198-205. e1. doi: 10.1016/j.ajo.2008.08.032. [DOI] [PubMed]
23. Na KS, Mok JW, Kim JY, Rho CR, Joo CK. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. Invest Ophthalmol Vis Sci. 2012 Aug; 53(9): 5443-50. doi: 10.1167/iovs.11-9417. [DOI] [PubMed]
24. Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther. 2012 May; 14(3): R127. doi: 10.1186/ar3857. [DOI] [PubMed]
25. Pflugfelder SC. Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011 Dec; 152(6): 900-909.e1. doi: 10.1016/j.ajo.2011.08.023. [DOI] [PubMed]
26. Berman MB, Barber JC, Talamo RC, Langley CE. Corneal ulceration and the serum antiproteases. I. Alpha 1-antitrypsin. Invest Ophthalmol. 1973 Oct; 12(10): 759-70. [PubMed]
27. Punyiczki M, Berta A, Tözsér J. Study of neutral proteinases of human tear samples using gels containing copolymerized substrates. Clin Chem Enzyme Commun. 1988; 1(2): 115-24. [Link]
28. Fox RI, Liu AY. Sjögren's syndrome in dermatology. Clin Dermatol. 2006 Sep-Oct; 24(5): 393-413. doi: 10.1016/j.clindermatol.2006.07.005. [DOI] [PubMed]
29. Fox RI. Sjögren's syndrome. Lancet. 2005 Jul; 366(9482): 321-31. doi: 10.1016/S0140-6736(05)66990-5. [DOI] [PubMed]
30. 30. Allanore Y, Parc C, Monnet D, Brézin AP, Kahan A. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. Ann Rheum Dis. 2004 Oct; 63(10): 1276-78. doi: 10.1136/ard.2003.013540. [DOI] [PubMed]
31. Gezer A, Tuncer S, Canturk S, Kasapoglu E, Cimen AO, Inanc M. Bilateral acquired Brown syndrome in systemic scleroderma. J AAPOS. 2005 Apr; 9(2): 195-97. doi: 10.1016/j.jaapos.2004.11.019. [DOI] [PubMed]
32. Konuk O, Ozdek S, Onal B, Tiftikçioğlu Y, Gürelik G, Hasanreisoğlu B. Ocular ischemic syndrome presenting as central retinal artery occlusion in scleroderma. Retina. 2006 Jan; 26(1): 102-104. doi: 10.1097/00006982-200601000-00017. [DOI] [PubMed]
33. Ushiyama O, Ushiyama K, Yamada T, Koarada S, Tada Y, Suzuki N, et al. Retinal findings in systemic sclerosis: a comparison with nailfold capillaroscopic patterns. Ann Rheum Dis. 2003 Mar; 62(3): 204-207. doi: 10.1136/ard.62.3.204. [DOI] [PubMed]
34. Borda E, Camusso JJ, Perez Leiros C, Bacman S, Hubscher O, Arana R, Sterin-Borda L. Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren's syndrome. Mol Cell Biochem. 1996 Oct-Nov; 163-164: 335-41. doi: 10.1007/BF00408674. [DOI] [PubMed]
35. García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjögren's syndrome. Arch Med Res. 2006 Nov; 37(8): 921-32. doi: 10.1016/j.arcmed.2006.08.002. [DOI] [PubMed]
36. Xanthou G, Tapinos NI, Polihronis M, Nezis IP, Margaritis LH, Moutsopoulos HM. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome. Clin Exp Immunol. 1999 Oct; 118(1): 154-63. doi: 10.1046/j.1365-2249.1999.01037.x. [DOI] [PubMed]
37. Emre S, Kayikçioğlu O, Ateş H, Cinar E, Inceoğlu N, Yargucu F, et al. Corneal hysteresis, corneal resistance factor, and intraocular pressure measurement in patients with scleroderma using the reichert ocular response analyzer. Cornea. 2010 Jun; 29(6): 628-31. doi: 10.1097/ICO.0b013e3181c3306a. [DOI] [PubMed]
38. Mancel E, Janin A, Gosset D, Hatron PY, Gosselin B. Conjunctival biopsy in scleroderma and primary Sjögren's syndrome. Am J Ophthalmol. 1993 Jun; 115(6): 792-99. doi: 10.1016/s0002-9394(14)73650-5. [DOI] [PubMed]
39. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017 Jul; 15(3): 334-65. doi: 10.1016/j.jtos.2017.05.003. [DOI] [PubMed]
40. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar; 52(4): 1994-2005. doi: 10.1167/iovs.10-6997e. [DOI] [PubMed]
41. Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjögren syndrome. Ophthalmology. 1998 Aug; 105(8): 1485-88. doi: 10.1016/S0161-6420(98)98033-2. [DOI] [PubMed]
42. Geerling G, Baudouin C, Aragona P, Rolando M, Boboridis KG, Benítez-Del-Castillo JM, et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf. 2017 Apr; 15(2): 179-92. doi: 10.1016/j.jtos.2017.01.006. [DOI] [PubMed]
43. Eballé AO, Ellong A, Wang RE, Mbakop CY, Bella AL, Mvogo CE. [Meibomian glands dysfunction and ocular surface in black people]. J Fr Ophtalmol. 2019 Feb; 42(2): 127-32. doi: 10.1016/j.jfo.2018.06.008. [Article in French] [DOI] [PubMed]
44. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004 Apr; 2(2): 149-65. doi: 10.1016/s1542-0124(12)70150-7. [DOI] [PubMed]
45. Arita R, Mizoguchi T, Kawashima M, Fukuoka S, Koh S, Shirakawa R, et al. Meibomian Gland Dysfunction and Dry Eye Are Similar but Different Based on a Population-Based Study: The Hirado-Takushima Study in Japan. Am J Ophthalmol. 2019 Nov; 207: 410-18. doi: 10.1016/j.ajo.2019.02.024. [DOI] [PubMed]
46. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017 Jul; 15(3): 438-510. doi: 10.1016/j.jtos.2017.05.011. [DOI] [PubMed]
47. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011 Mar; 52(4): 1938-78. doi: 10.1167/iovs.10-6997c. [DOI] [PubMed]
48. Alvarenga LS, Mannis MJ. Ocular rosacea. Ocul Surf. 2005 Jan; 3(1): 41-58. doi: 10.1016/s1542-0124(12)70121-0. [DOI] [PubMed]
49. Sullivan DA, Bélanger A, Cermak JM, Bérubé R, Papas AS, Sullivan RM, et al. Are women with Sjögren's syndrome androgen-deficient? J Rheumatol. 2003 Nov; 30(11): 2413-19. [PubMed]
50. Sullivan DA. Possible mechanisms involved in the reduced tear secretion in Sjögren’s Syndrome: state of the art. Amsterdam: Kugler Press. 1994; pp: 9-13. [Link]
51. Hemady R, Chu W, Foster CS. Keratoconjunctivitis sicca and corneal ulcers. Cornea. 1990 Apr; 9(2): 170-73. [PubMed]
52. Villani E, Galimberti D, Viola F, Mapelli C, Del Papa N, Ratiglia R. Corneal involvement in rheumatoid arthritis: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2008 Feb; 49(2): 560-64. doi: 10.1167/iovs.07-0893. [DOI] [PubMed]
53. Bloomfield SE, Becker CG, Christian CL, Nauheim JS. Bilateral necrotising scleritis with marginal corneal ulceration after cataract surgery in a patient with vasculitis. Br J Ophthalmol. 1980 Mar; 64(3): 170-74. doi: 10.1136/bjo.64.3.170. [DOI] [PubMed]
54. Sainz de la Maza M, Foster CS. Necrotizing scleritis after ocular surgery. A clinicopathologic study. Ophthalmology. 1991 Nov; 98(11): 1720-26. doi: 10.1016/s0161-6420(91)32062-1. [DOI] [PubMed]
55. Rao NA, Marak GE, Hidayat AA. Necrotizing scleritis. A clinico-pathologic study of 41 cases. Ophthalmology. 1985 Nov; 92(11): 1542-49. [PubMed]
56. Harrison SA, Mondino BJ, Mayer FJ. Scleral fibroblasts. Human leukocyte antigen expression and complement production. Invest Ophthalmol Vis Sci. 1990 Nov; 31(11): 2412-19. [PubMed]
57. Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol. 1972 Nov; 56(11): 800-804. doi: 10.1136/bjo.56.11.800. [DOI] [PubMed]
58. Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology. 1980 Feb; 87(2): 140-50. doi: 10.1016/s0161-6420(80)35272-x. [DOI] [PubMed]
59. Nguyen QD, Foster CS. Systemic lupus erythematosus and the eye. Int Ophthalmol Clin. 1998; 38(1): 33-60. doi: 10.1097/00004397-199803810-00005. [DOI] [PubMed]
60. Davies JB, Rao PK. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2008 Nov; 19(6): 512-18. doi: 10.1097/icu.0b013e3283126d34. [DOI] [PubMed]
61. Calvo P, Pablo L. Managing IBD outside the gut: ocular manifestations. Dig Dis. 2013; 31(2): 229-32. doi: 10.1159/000353375. [DOI] [PubMed]
62. Thomas AS, Lin P. Ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol. 2016 Nov; 27(6): 552-60. doi: 10.1097/ICU.0000000000000310. [DOI] [PubMed]
63. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr; 96(4): 1116-22. doi: 10.1111/j.1572-0241.2001.03756.x. [DOI] [PubMed]
64. Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res. 2004 Mar; 78(3): 513-25. doi: 10.1016/j.exer.2003.09.023. [DOI] [PubMed]
65. Tuisku IS, Konttinen YT, Konttinen LM, Tervo TM. Alterations in corneal sensitivity and nerve morphology in patients with primary Sjögren's syndrome. Exp Eye Res. 2008 Jun; 86(6): 879-85. doi: 10.1016/j.exer.2008.03.002. [DOI] [PubMed]
66. Goodisson LA, Bourne JT, Maharajan S. A case of bilateral peripheral ulcerative keratitis following treatment with rituximab. Rheumatology (Oxford). 2010 Mar; 49(3): 609-10. doi: 10.1093/rheumatology/kep390. [DOI] [PubMed]
67. Smith VA, Hoh HB, Easty DL. Role of ocular matrix metalloproteinases in peripheral ulcerative keratitis. Br J Ophthalmol. 1999 Dec; 83(12): 1376-83. doi: 10.1136/bjo.83.12.1376. [DOI] [PubMed]
68. De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD 3rd, Fang B, Zheng X, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009 May; 2(3): 243-53. doi: 10.1038/mi.2009.5. [DOI] [PubMed]
69. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012 Jun; 122(11): 487-511. doi: 10.1042/CS20110496. [DOI] [PubMed]
70. Young S. Ocular involvement in connective tissue disorders. Curr Allergy Asthma Rep. 2005 Jul; 5(4): 323-26. doi: 10.1007/s11882-005-0076-y. [DOI] [PubMed]
71. Eustace P, Pierse D. Ocular psoriasis. Br J Ophthalmol. 1970 Dec; 54(12): 810-13. doi: 10.1136/bjo.54.12.810. [DOI] [PubMed]
72. Kervick GN, Pflugfelder SC, Haimovici R, Brown H, Tozman E, Yee R. Paracentral rheumatoid corneal ulceration. Clinical features and cyclosporine therapy. Ophthalmology. 1992 Jan; 99(1): 80-88. doi: 10.1016/s0161-6420(92)32006-8. [DOI] [PubMed]
73. Murray PI, Rauz S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol. 2016 Oct; 30(5): 802-25. doi: 10.1016/j.berh.2016.10.007. [DOI] [PubMed]
74. Zlatanović G, Veselinović D, Cekić S, Zivković M, Dorđević-Jocić J, Zlatanović M. Ocular manifestation of rheumatoid arthritis-different forms and frequency. Bosn J Basic Med Sci. 2010 Nov; 10(4): 323-27. doi: 10.17305/bjbms.2010.2680. [DOI] [PubMed]
75. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface. 2017 Jul; 15(3): 276-83. doi: 10.1016/j.jtos.2017.05.008. [Link] [DOI]
76. Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014 Jul; 40(4): 248-56. doi: 10.1097/ICL.0000000000000042. [DOI] [PubMed]
77. Lemp MA. Dry eye (Keratoconjunctivitis Sicca), rheumatoid arthritis, and Sjögren's syndrome. Am J Ophthalmol. 2005 Nov; 140(5): 898-99. doi: 10.1016/j.ajo.2005.06.031. [DOI] [PubMed]
78. Cimmino MA, Salvarani C, Macchioni P, Montecucco C, Fossaluzza V, Mascia MT, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int. 2000; 19(6): 213-17. doi: 10.1007/pl00006853. [DOI] [PubMed]
79. Preble JM, Silpa-archa S, Foster CS. Ocular involvement in systemic lupus erythematosus. Curr Opin Ophthalmol. 2015 Nov; 26(6): 540-45. doi: 10.1097/ICU.0000000000000209. [DOI] [PubMed]
80. Taylor S, Pacheco P, Lightman S. Dry Eyes in Rheumatic Disease. Current Rheumatology Reviews. 2011; 7(1): 3-14. doi: 10.2174/157339711794474602. [Link] [DOI]
81. Sjögren H. Zur kenntnis der keratoconjunctivitis sicca (keratitis filiformis bei hypofunktion der tränendrüsen). Stockholm: Centraltryckeriet. 1933. [German] [Link]
82. Henrich CF, Ramulu PY, Akpek EK. Association of dry eye and inflammatory systemic diseases in a tertiary care-based sample. Cornea. 2014 Aug; 33(8): 819-25. doi: 10.1097/ICO.0000000000000173. [DOI] [PubMed]
83. Wang H, Wang PB, Chen T, Zou J, Li YJ, Ran XF, et al. Analysis of Clinical Characteristics of Immune-Related Dry Eye. J Ophthalmol. 2017; 2017: 8532397. doi: 10.1155/2017/8532397. [DOI] [PubMed]
84. West RH, Barnett AJ. Ocular involvement in scleroderma. Br J Ophthalmol. 1979 Dec; 63(12): 845-47. doi: 10.1136/bjo.63.12.845. [DOI] [PubMed]
85. Gomes Bde A, Santhiago MR, Magalhães P, Kara-Junior N, Azevedo MN, Moraes HV Jr. Ocular findings in patients with systemic sclerosis. Clinics (Sao Paulo). 2011; 66(3): 379-85. doi: 10.1590/s1807-59322011000300003. [DOI] [PubMed]
86. Rentka A, Nagy A, Harsfalvi J, Szucs G, Szekanecz Z, Gesztelyi R, et al. Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. Rheumatol Int. 2017 Nov; 37(11): 1835-45. doi: 10.1007/s00296-017-3794-2. [DOI] [PubMed]
87. Viso E, Rodríguez-Ares MT, Abelenda D, Oubiña B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci. 2012 May; 53(6): 2601-606. doi: 10.1167/iovs.11-9228. [DOI] [PubMed]
88. Sullivan DA, Wickham LA, Krenzer KL, Rocha EM, Toda I. Aqueous tear deficiency in Sjögren’s syndrome: possible causes and potential treatment. In: Pleyer U, Hartmann C, Sterry W, eds. Oculodermal Diseases - Immunology of Bullous Oculo-Muco-Cutaneous Disorders. Buren. The Netherlands: Aeolus Press. 1997; pp: 95-152.
89. Foulks GN, Lemp MA, Jester J, Sutphin J, Murube J, Novack G. Report of the international dry eye workshop. The Ocular Surface. 2007; 5(2): 65-203. [Link]
90. Goto E, Matsumoto Y, Kamoi M, Endo K, Ishida R, Dogru M, et al. Tear evaporation rates in Sjögren syndrome and non-Sjögren dry eye patients. Am J Ophthalmol. 2007 Jul; 144(1): 81-85. doi: 10.1016/j.ajo.2007.03.055. [DOI] [PubMed]
91. Akpek EK, Mathews P, Hahn S, Hessen M, Kim J, Grader-Beck T, et al. Ocular and systemic morbidity in a longitudinal cohort of Sjögren's syndrome. Ophthalmology. 2015 Jan; 122(1): 56-61. doi: 10.1016/j.ophtha.2014.07.026. [DOI] [PubMed]
92. Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea. 2009 Jun; 28(5): 493-97. doi: 10.1097/ICO.0b013e31818d3846. [DOI] [PubMed]
93. Fox RI. Sjögren's syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs. 2000 Sep; 9(9): 2007-16. doi: 10.1517/13543784.9.9.2007. [DOI] [PubMed]
94. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002 Feb; 133(2): 181-86. doi: 10.1016/s0002-9394(01)01365-4. [DOI] [PubMed]
95. Vivino FB, Minerva P, Huang CH, Orlin SE. Corneal melt as the initial presentation of primary Sjögren's syndrome. J Rheumatol. 2001 Feb; 28(2): 379-82. [PubMed]
96. Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjögren's syndrome. Arch Ophthalmol. 1980 Jan; 98(1): 89-94. doi: 10.1001/archopht.1980.01020030091006. [DOI] [PubMed]
97. Mathews PM, Hahn S, Hessen M, Kim J, Grader-Beck T, Birnbaum J, et al. Ocular complications of primary Sjögren syndrome in men. Am J Ophthalmol. 2015 Sep; 160(3): 447-452.e1. doi: 10.1016/j.ajo.2015.06.004. [DOI] [PubMed]
98. Krachmer JH, Laibson PR. Corneal thinning and perforation in Sjögren's syndrome. Am J Ophthalmol. 1974 Dec; 78(6): 917-20. doi: 10.1016/0002-9394(74)90801-0. [DOI] [PubMed]
99. Squirrell DM, Winfield J, Amos RS. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. Rheumatology (Oxford). 1999 Dec; 38(12): 1245-48. doi: 10.1093/rheumatology/38.12.1245. [DOI] [PubMed]
100. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999 Mar-Apr; 43(5): 379-96. doi: 10.1016/s0039-6257(98)00051-4. [DOI] [PubMed]
101. Yagci A. Update on peripheral ulcerative keratitis. Clin Ophthalmol. 2012; 6: 747-54. doi: 10.2147/OPTH.S24947. [DOI] [PubMed]
102. Tauber J, Sainz de la Maza M, Hoang-Xuan T, Foster CS. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea. 1990 Jan; 9(1): 66-73. [PubMed]
103. Pogson C. Acanthamoeba keratitis. J Ophthalmic Nurs Technol. 1993 May-Jun; 12(3): 114-16. [PubMed]
104. Kedhar SR, Belair ML, Jun AS, Sulkowski M, Thorne JE. Scleritis and peripheral ulcerative keratitis with hepatitis C virus-related cryoglobulinemia. Arch Ophthalmol. 2007 Jun; 125(6): 852-53. doi: 10.1001/archopht.125.6.852. [DOI] [PubMed]
105. Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006; 15(1): 3-12. doi: 10.1191/0961203306lu2250rr. [DOI] [PubMed]
106. Jensen JL, Bergem HO, Gilboe IM, Husby G, Axéll T. Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. J Oral Pathol Med. 1999 Aug; 28(7): 317-22. doi: 10.1111/j.1600-0714.1999.tb02047.x. [DOI] [PubMed]
107. Klinkhoff AV, Beattie CW, Chalmers A. Retinopathy in systemic lupus erythematosus: relationship to disease activity. Arthritis Rheum. 1986 Sep; 29(9): 1152-56. doi: 10.1002/art.1780290914. [DOI] [PubMed]
108. Bajwa A, Foster SC. Ocular manifestations of systemic lupus erythematosus. J Clin Cell Immunol. 2014; 5: 191. doi: 10.4172/2155-9899.1000191. [View at Publisher] [DOI]
109. Read RW, Weiss AH, Sherry DD. Episcleritis in childhood. Ophthalmology. 1999 Dec; 106(12): 2377-79. doi: 10.1016/S0161-6420(99)90520-1. [DOI] [PubMed]
110. Pavesio CE, Meier FM. Systemic disorders associated with episcleritis and scleritis. Curr Opin Ophthalmol. 2001 Dec; 12(6): 471-78. doi: 10.1097/00055735-200112000-00013. [DOI] [PubMed]
111. Heiligenhaus A, Dutt JE, Foster CS. Histology and immunopathology of systemic lupus erythematosus affecting the conjunctiva. Eye (Lond). 1996; 10(Pt 4): 425-32. doi: 10.1038/eye.1996.94. [DOI] [PubMed]
112. Hakin KN, Watson PG. Systemic associations of scleritis. Int Ophthalmol Clin. 1991; 31(3): 111-29. doi: 10.1097/00004397-199103130-00010. [DOI] [PubMed]
113. Frith P, Burge SM, Millard PR, Wojnarowska F. External ocular findings in lupus erythematosus: a clinical and immunopathological study. Br J Ophthalmol. 1990 Mar; 74(3): 163-67. doi: 10.1136/bjo.74.3.163. [DOI] [PubMed]
114. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995 Apr; 102(4): 687-92. doi: 10.1016/s0161-6420(95)30970-0. [DOI] [PubMed]
115. Varga JH, Wolf TC. Bilateral transient keratoendotheliitis associated with systemic lupus erythematosus. Ann Ophthalmol. 1993 Jun; 25(6): 222-23. [PubMed]
116. Adan CB, Trevisani VF, Vasconcellos M, de Freitas D, de Souza LB, Mannis M. Bilateral deep keratitis caused by systemic lupus erythematosus. Cornea. 2004 Mar; 23(2): 207-209. doi: 10.1097/00003226-200403000-00017. [DOI] [PubMed]
117. Lin YC, Wang AG, Yen MY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol. 2009 Mar; 87(2): 204-10. doi: 10.1111/j.1755-3768.2008.01193.x. [DOI] [PubMed]
118. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012; 2012: 290898. doi: 10.1155/2012/290898. [DOI] [PubMed]
119. Merrill JT, Buyon JP, Utset T. A 2014 update on the management of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2014 Oct; 44(2): e1-2. doi: 10.1016/j.semarthrit.2014.09.013. [DOI] [PubMed]
120. Arnaud L, Van Vollenhoven R. Advanced handbook of systemic lupus erythematosus. Springer. 2018; pp: 151-67. [Link]
121. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004 Mar; 10(2): 135-39. doi: 10.1097/00054725-200403000-00012. [DOI] [PubMed]
122. Salmon JF, Wright JP, Murray AD. Ocular inflammation in Crohn's disease. Ophthalmology. 1991 Apr; 98(4): 480-84. doi: 10.1016/s0161-6420(91)32268-1. [DOI] [PubMed]
123. Gomes BA, Santhiago MR, Jorge PA, Kara-José N, Moraes HV Jr, Kara-Junior N. Corneal involvement in systemic inflammatory diseases. Eye Contact Lens. 2015 May; 41(3): 141-44. doi: 10.1097/ICL.0000000000000141. [DOI] [PubMed]
124. Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2016 Apr; 10(4): 429-36. doi: 10.1093/ecco-jcc/jjv232. [DOI] [PubMed]
125. Hopkins DJ, Horan E, Burton IL, Clamp SE, de Dombal FT, Goligher JC. Ocular disorders in a series of 332 patients with Crohn's disease. Br J Ophthalmol. 1974 Aug; 58(8): 732-37. doi: 10.1136/bjo.58.8.732. [DOI] [PubMed]
126. Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Aug; 16(8): 1393-96. doi: 10.1002/ibd.21180. [DOI] [PubMed]
127. da Rocha Lima B, Pichi F, Lowder CY. Night blindness and Crohn's disease. Int Ophthalmol. 2014 Oct; 34(5): 1141-44. doi: 10.1007/s10792-014-9940-x. [DOI] [PubMed]
128. Abegunde AT, Muhammad BH, Ali T. Preventive health measures in inflammatory bowel disease. World J Gastroenterol. 2016 Sep; 22(34): 7625-44. doi: 10.3748/wjg.v22.i34.7625. [DOI] [PubMed]
129. Knox DL, Schachat AP, Mustonen E. Primary, secondary and coincidental ocular complications of Crohn's disease. Ophthalmology. 1984 Feb; 91(2): 163-73. doi: 10.1016/s0161-6420(84)34322-6. [DOI] [PubMed]
130. Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. Scientific World Journal. 2015; 2015: 438402. doi: 10.1155/2015/438402. [DOI] [PubMed]
131. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med. 1988 Oct; 85(4A): 23-29. doi: 10.1016/0002-9343(88)90358-0. [DOI] [PubMed]
132. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996 Mar; 55(3): 187-89. doi: 10.1136/ard.55.3.187. [DOI] [PubMed]
Send email to the article author

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ansari-Astaneh M, Es’haghi A, Keshavarzian E, Sadeghi J, Kiarudi M Y. Laser Therapy in Corneal Refractive of Patients with Systemic Autoimmune Disorders. J Gorgan Univ Med Sci 2023; 25 (2) :12-21
URL: http://goums.ac.ir/journal/article-1-4285-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 25, Issue 2 (7-2023) Back to browse issues page
مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.04 seconds with 36 queries by YEKTAWEB 4652